UroAlert - GU Oncology Weekly

November 26, 2025

Videos

Peer-to-Peer Clinical Conversations

Investigational Therapies Target STEAP1 and DLL3 in Advanced Prostate Cancer - Rahul Aggarwal

Rahul Aggarwal

Zachary Klaassen hosts Rahul Aggarwal to discuss therapeutic targets in metastatic castration-resistant prostate cancer, focusing on cell surface antigens including STEAP1, DLL3, PSMA, and KLK2.

IBCG Recommendations for Intermediate-Risk NMIBC Definitions and Management - Roger Li

Roger Li

Roger Li discusses the International Bladder Cancer Group recommendations for intermediate-risk non-muscle invasive bladder cancer.

Conference Coverage

ASTRO 2025: Trials in Progress: CONSOLIDATE – Concurrent Radiotherapy with Enfortumab vedotin for Locally Advanced Bladder Cancer

ASTRO 2025: Comparing PSMA PET/CT and MRI in Prostate Radiotherapy Planning: Which Modality Better Predicts Seminal Vesicle Involvement?

ASTRO 2025: Radiation Oncology-Biology Integration Network (ROBIN) -Oligometastasis Center

ASTRO 2025: Bladder Only vs. Whole Pelvis Radiotherapy in Trimodality Treatment for Lymph Node Negative Urothelial Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Safety of transurethral resection of bladder tumor in octogenarians: a NSQIP analysis.

Refining Active Surveillance Eligibility in Intermediate-risk Non-muscle-invasive Bladder Cancer: The Impact of Time to First Recurrence.

The role of lasers in the management of bladder tumors.

Intravesical BCG for bladder cancer treatment complicated by disseminated BCG (BCGosis) with pericardial effusion and tamponade.

Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study.

Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction.

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality.

Circulating Tumor DNA in Muscle-invasive Bladder Cancer: Promise, Pitfalls, and Path Forward.

Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.

Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experience.

Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data.

Development and Analytical Validation of a Multiplex Diagnostic qPCR-Array as a Potential Application in Predicting the Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

Functional and surgical outcomes after penile surgery for cancer: Comparison between conservative and non-conservative surgery.

Low GATA3 predicts worse survival in penile cancer.

Sentinel Node Mapping in Penile Cancer: An Update on Methods and Pitfalls.

Penile cancer and lymph node management: a call for standardization.

Renal Cancer

Surveillance Protocols After Nephrectomy or Ablation in Renal Cancer: A Scoping Review of Variations, Evidence, and Research Gaps.

Survival of patients with metastatic renal cell carcinoma with or without brain metastases.

Measurement of renal tumor size: the impact of 2D versus 3D methods on the T-stage.

French recommendations on multi-gene panel testing in renal cell carcinoma.

Neoadjuvant pembrolizumab and tyrosine kinase inhibitor to facilitate imperative partial nephrectomy for renal cell carcinoma.

Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.

Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter study.

Unraveling Smooth Muscle-Rich Renal Cell Carcinoma: Clinical, Oncological, Genetic, and Pathological Insights.

Partial vs. radical nephrectomy in pT3a renal cancer: Cancer-specific mortality according to fat invasion pattern.

Titrating Cabozantinib in Metastatic Renal Cell Carcinoma Patients Using Goldilocks Principle: A Real-World Evidence Study - Beyond the Abstract

Partial nephrectomy Vs. Percutaneous thermal ablation of small renal masses.

Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell Carcinoma - Beyond the Abstract

Prostate Cancer

Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer.

Incidental findings on prostate MRI in a population-based screening setting.

Molecular tumor volume on PSMA PET/CT is an independent imaging biomarker associated with progression-free survival in patients with oligorecurrent prostate cancer.

From lutetium to terbium: a new era in PSMA-targeted radioligand therapy for mCRPC patients.

Can Prostate Cancer Screening Reduce Mortality in Men Aged 75-79 Years? A Protocol for Target-trial Emulation.

Detection of clinically significant prostate cancer using targeted MRI-informed microultrasound biopsy.

Diet quality, eating behaviour, and mental health outcomes of prostate cancer survivors.

Understanding the role of statin use on advanced prostate cancer outcomes: Does the statin type, cumulative dose, or duration impact survival?

Circulating Tumor Cells and Clinical Outcomes in Men with Metastatic Castration-sensitive Prostate Cancer Treated with Enzalutamide and Docetaxel: An Analysis of the ENZADA Trial.

Clinical Effectiveness of Oral Relugolix in Advanced Prostate Cancer: A Structured Review of Current Primary Research.

Non-coding genetic variants underlying higher prostate cancer risk in men of African ancestry.

PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data.

Effect of TGF-β mediated phenotypic changes on prostate cancer cell anoikis response.

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age.

Joint Biochemical & Genetic Prostate Cancer Risk Stratification.

Effect of Post-Diagnosis Diet and Lifestyle on Clinical Outcomes in Prostate Cancer Survivors: A Systematic Review.

Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.

The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer.

Monitoring intra- and inter-fraction motion using transperineal ultrasound (TPUS), for patients receiving stereotactic ablative radiotherapy (SABR) to the prostate.

Prostate Cancer Screening Practices Among High-Risk Patients: A Retrospective Analysis.

Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer.

Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment.

DGAT1 as a Racially Divergent Driver of Carcinoma-Associated Fibroblast Activation Drives Tumorigenic Pathways via ERK1/2 Signaling in Prostate Cancer.

Perioperative Outcomes Comparing the DaVinci 5 with DaVinci Xi in Patients Undergoing Robotic-Assisted Radical Prostatectomy - Beyond the Abstract

Reappraisal of Neuroendocrine Tumor Classification of the Prostate Gland: Translating Molecular Insights into Clinical Practice - Beyond the Abstract

Outcomes of robotic prostatectomy with lymph node removal and early hormone therapy for locally advanced prostate cancer (pT3-4N0-1M0).

Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging - Beyond the Abstract

The role of the human microbiome in prostate cancer: a systematic review from diagnosis to treatment.

Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.

Claims-Based Analysis of National Utilization Patterns and Regional Variability of Prostate Cancer Ablative Therapies: A Medicare Study.

Drivers Influencing Prostate Cancer Treatment Decision making - A Qualitative Analysis of Underrepresented Men across the US.

Pathologist-like explainable AI for interpretable Gleason grading in prostate cancer.

Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN.

Methylation reprogramming associated with aggressive prostate cancer and ancestral disparities.

Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus.

Combined MYC Activation and PTEN Loss Drives Molecular Features of Aggressive Preinvasive Lesions in Mouse Prostate.

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.

EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression.

Artificial intelligence defines spatial patterns of tumor-infiltrating lymphocytes highly associated with outcome - a pan-GI cancer study.

Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer.

Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance.

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

Prostate cancer screening in transgender women/transfeminine persons: Building on Canadian evidence.

Initial Multicenter Experience with [161Tb]Tb-PSMA in [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results.

Optimizing [212Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.

α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer.

Diagnostic Accuracy of Abbreviated Biparametric MRI for Prostate Cancer Screening: A Prospective Feasibility Study (ReIMAGINE Study) - Beyond the Abstract

Transperineal 3T MRI-Guided and Transrectal MRI-Ultrasound Fusion Prostate Biopsies: Do Lesion Location and Size Impact Diagnostic Yield? - Beyond the Abstract

AI-Generated Questions for Urological Competency Assessment: A Prospective Educational Study - Beyond the Abstract

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.

Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.

IGF-1 regulates cancer cell immune evasion in prostate cancer.

Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer.

Abiraterone vs Enzalutamide Among US Veterans With Metastatic Hormone-Sensitive Prostate Cancer.

Discovery and performance of DNA methylation panels for cancer detection and classification in blood.

Spatially organized lymphocytic microenvironments in high grade primary prostate tumors.

Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.

Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Identifying prognostic targets in metastatic prostate cancer beyond AR.

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.

Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617.

Upper Tract Tumors

Competing risk analysis for predicting distant metastasis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy: based on a large dataset from a national medical center.

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.

Global Research Trends and Frontiers in Upper Tract Urothelial Carcinoma: A Comprehensive Visualization and Bibliometric Analysis.

Testicular Cancer

Sperm Telomere Interactions Are Impaired in Testicular Cancer Before and After Adjuvant Therapy.

Zip code, race, and ethnicity: The impact of socioeconomic hardship on cancer presentation and survival among patients with testicular germ cell tumors.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC